Top IT chief Perakslis steps down at FDA

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Top IT chief Perakslis steps down at FDA

Eric Perakslis left his job at the FDA as chief information officer. The IT specialist joined the agency in 2011 after heading informatics R&D at Johnson & Johnson ($JNJ), bringing with him his expertise in open-source and cloud computing. At the FDA, Perakslis completed a new blueprint for IT and took the lead on innovation that would help speed up medical device reviews. He left under uncertain terms, and an interim CIO will serve in the meantime, according to the FDA. Article

Eric Perakslis -- FDA
Perakslis stepped down from a chief information officer position.

Lynn Kramer -- Eisai
Kramer joins Eisai as the chief clinical officer of Eisai Product Creation Systems.


Dr. Lynn Kramer has been appointed as chief clinical officer of Eisai Product Creation Systems. Kramer joined Eisai Inc., the U.S. subsidiary of the Japanese Eisai Co., in 2007 as executive vice president of global clinical research, and most recently, he became president of the Neuroscience and General Medicine Product Creation Unit as well as the Scientific and Operational Clinical Support Core Functional Unit. Release

> Thomas Dietz, chairman and CEO of Waypoint Holdings, has joined the board of Transcept Pharmaceuticals ($TSPT) as an independent director. Release


Thi-Sau Migone joins Igenica as chief scientific officer. Migone was previously at Human Genome Sciences, where she held a variety of executive positions and most recently served as vice president of research. Release

> Zosano Pharma has appointed Chris Krueger as the company's chief business officer. Prior to joining Zosano, Krueger served as senior vice president and chief business officer at Ardea Biosciences. Release

> Oxford, U.K.-based Karus Therapeutics has appointed a new scientific advisory board that includes R&D professionals from both academia and pharma. More

> Vaccines developer Scancell Holdings has appointed Peter Allen as a nonexecutive director to its board. Allen is currently chairman of Clinigen PLC, Chroma Therapeutics, ProStrakan plc and Future plc and a nonexecutive director of Oxford Nanopore Technologies. Announcement

> Dr. Robert Garland, a partner at New Enterprise Associates, has joined Cleave Biosciences' board of directors. Release

> Kevin Buchi has joined the board of Australian Benitec Biopharma. Buchi served as CEO of Cephalon through its $6.8 billion acquisition by Teva Pharmaceutical Industries ($TEVA) in October 2011. Release

> Swedish Orphan Biovitrum appointed Mats-Olof Wallin as the company's chief financial officer. With more than 30 years of experience in the industry, Wallin was most recently CFO of the Swedish company Biotage. Release

> Prime Therapeutics named Glen Laschober as its chief operating officer. Laschober previously served as vice president and COO at US Oncology, the nation's largest oncology company. Release

> Steve Jackson, co-founder and chief scientific officer at Mission Therapeutics, became an associate faculty member at the Wellcome Trust Sanger Institute, where his team will research cell response to DNA damage. Release

> Teva Pharmaceutical appointed Ichiro Kikushige as its CEO in Japan. Kikushige comes from Eli Lilly Japan K.K., where he was senior director of sales. Release

> Aptuit named Kurt Dinkelacker as its executive vice president and chief financial officer and Kevin Duffield as vice president of sales. Release

Medical Devices

Physik Instrumente brought on William Culpi as engineering chief of its Pl miCos U.S.A. products. Culpi was formerly vice president at MICOS USA, where he developed a line of piezo positioning systems. Release


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.